文献速递神经MRPET

炎症性多发性硬化中的脉络丛增大:3.0-T MRI与转运蛋白PET评估

Choroid Plexus Enlargement in Inflammatory Multiple Sclerosis: 3.0-T MRI and Translocator Protein PET Evaluation.
PubMed 文献 · Radiology · 2021-07-13

本研究为97例多发性硬化患者(61例复发缓解型、36例进展型)与44名健康对照的二次分析,患者脉络丛体积较对照大35%(P=0.004),且与白质病灶负荷、丘脑及正常表现白质18F-DPA-714结合及年化复发率相关;患者脉络丛18F-DPA-714摄取较对照高18.5%(P=0.01)。

要点

  • 多发性硬化患者脉络丛体积较健康对照大35%(P=0.004),复发缓解型亚组亦增大(P=0.008)。
  • 钆增强病灶患者脉络丛体积大于无强化病灶患者(P<0.001)。
  • 脉络丛体积与白质病灶负荷、丘脑及正常表现白质18F-DPA-714结合、复发缓解型年化复发率相关。

核心结论

  • 多发性硬化患者脉络丛增大且存在炎症,尤其在具有炎症特征的复发缓解型患者中;脉络丛体积分析可能成为多发性硬化影像标志物。

研究设计与样本

  • 三次前瞻性3.0-T脑MRI研究的二次分析,纳入97例多发性硬化患者(61例复发缓解型、36例进展型)和44名健康对照,研究时间为2009年5月至2017年9月;其中37例患者和19名对照另行接受18F-DPA-714 PET检查神经炎症。

关键影像表现/征象

  • 脉络丛在三维T1加权图像上手动分割,体积以颅内体积比值表示。
  • 多发性硬化患者脉络丛体积较健康对照大35%(均值15.9×10-4±4.5 vs 11.8×10-4±3.8,P=0.004)。
  • 复发缓解型患者脉络丛体积大于健康对照(均值15.5×10-4±4.6,P=0.008)。
  • 钆增强病灶患者脉络丛体积大于无强化病灶患者(均值18.2×10-4±4.9 vs 14.9×10-4±4,P<0.001)。
  • 多发性硬化患者脉络丛18F-DPA-714摄取较对照高18.5%(均值0.778±0.23 vs 0.635±0.15,P=0.01)。

诊断标准与关键数值

  • 脉络丛体积与白质病灶负荷相关(r=0.39,95%CI:0.20,0.55,P<0.001)。
  • 脉络丛体积与丘脑18F-DPA-714结合相关(r=0.44,95%CI:0.22,0.72,P=0.04)。
  • 脉络丛体积与正常表现白质18F-DPA-714结合相关(r=0.5,95%CI:0.20,0.71,P=0.005)。
  • 复发缓解型患者脉络丛体积与年化复发率相关(r=0.37,95%CI:0.1,0.55,P=0.005)。
  • 复发缓解型患者脉络丛体积与18F-DPA-714摄取相关(r=0.57,95%CI:0.37,0.73,P=0.009)。

临床应用与阅片要点

  • 脉络丛体积可在三维T1加权图像上手动分割测量,并以颅内体积比值表达。
  • 18F-DPA-714 PET中,实质区域量化分布体积比,脉络丛炎症采用标准化摄取值。
  • 作者认为脉络丛体积分析可能成为多发性硬化影像标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Choroid plexuses (CPs) have been suggested as a key gateway for inflammation in experimental autoimmune encephalitis, but in vivo evidence of their involvement in multiple sclerosis (MS) is lacking. Purpose To assess CP volumetric and inflammatory changes in patients with MS versus healthy control participants. Materials and Methods This was a secondary analysis of 97 patients (61 with relapsing-remitting MS [RRMS] and 36 with progressive MS) and 44 healthy control participants who participated in three prospective 3.0-T brain MRI studies between May 2009 and September 2017. A subgroup of 37 patients and 19 healthy control participants also underwent translocator protein fluorine 18 (18F)-DPA-714 PET for neuroinflammation. Relapses and disability scores were collected at baseline and over 2 years. CPs were manually segmented on three-dimensional T1-weighted images; other brain volumes were additionally segmented. Volumes were expressed as a ratio of intracranial volume. The 18F-DPA-714 distribution volume ratio was quantified in parenchymal regions, whereas standardized uptake value was used for CP inflammation. Multivariable linear regression analyses were performed to assess CP volumetric and inflammatory differences between patients with MS and healthy control participants and correlations between CP volume and lesion load, brain volumes, 18F-DPA-714 uptake, and annualized relapse rate. Results Ninety-seven patients with MS (mean age, 42 years ± 12 [standard deviation]; 49 women) and 44 healthy control participants (mean age, 39 years ± 14; 23 women) underwent MRI. Thirty-seven patients with MS and 19 healthy control participants underwent PET. CPs were 35% larger in patients with MS (mean value, 15.9 × 10-4 ± 4.5) than in healthy control participants (mean value, 11.8 × 10-4 ± 3.8; P = .004). Subgroup analysis confirmed greater CP volume in patients with RRMS (mean value, 15.5 × 10-4 ± 4.6; P = .008) than in healthy control participants. CP enlargement was greater in patients with active lesions at MRI (mean volume, 18.2 × 10-4 ± 4.9 in patients with lesions that enhanced with gadolinium vs 14.9 × 10-4 ± 4 in patients with lesions that did not enhance with gadolinium; P < .001) and correlated with white matter lesion load (r = 0.39; 95% CI: 0.20, 0.55; P < .001) and 18F-DPA-714 binding in the thalami (r = 0.44; 95% CI: 0.22, 0.72; P = .04) and normal-appearing white matter (r = 0.5; 95% CI: 0.20, 0.71; P = .005). Moreover, it correlated with annualized relapse rate in patients with RRMS (r = 0.37; 95% CI: 0.1, 0.55; P = .005). Finally, patients with MS showed 18.5% higher CP 18F-DPA-714 uptake than control participants (mean value, 0.778 ± 0.23 vs 0.635 ± 0.15, respectively; P = .01). CP volume in patients with RRMS (r = 0.57; 95% CI: 0.37, 0.73; P = .009) correlated with higher 18F-DPA-714 uptake. Conclusion Choroid plexuses (CPs) are enlarged and inflamed in patients with multiple sclerosis (MS), particularly in those with relapsing-remitting MS with inflammatory profiles; CP volumetric analysis could represent an MS imaging marker. © RSNA, 2021 EudraCT no. 2008-004174-40; clinical trial registration nos. NCT02305264 and NCT01651520 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ricigliano VAG, Morena E, Colombi A, et al. Choroid Plexus Enlargement in Inflammatory Multiple Sclerosis: 3.0-T MRI and Translocator Protein PET Evaluation. Radiology. 2021. PMID: 34254858. doi:10.1148/radiol.2021204426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。